A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Tuberculosis, Pulmonary
Interventions
OTHER

a novel short regimen

An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.

All Listed Sponsors
collaborator

Hualien Tzu Chi General Hospital

OTHER

collaborator

Chest Hospital, Ministry of Health and Welfare, Taiwan

OTHER_GOV

collaborator

Chang-Hua Hospital

OTHER_GOV

collaborator

Taichung Veterans General Hospital

OTHER

collaborator

Taichung Hospital, Ministry of Health and Welfare

UNKNOWN

collaborator

Taoyuan General Hospital

OTHER_GOV

collaborator

Kaohsiung Veterans General Hospital.

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

lead

Taipei Medical University WanFang Hospital

OTHER